A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
LIPOPROTEIN-NMR
MessageTests for LDL-P, LDL-C, & HDL-C
Test Code
LIPO-NMR (123638) LC
Alias/See Also
NMR
CPT Codes
83704
Preferred Specimen
Plain Red - 2mL SERUM
NO GEL ACCEPTED
Other acceptable samples: EDTA plasma 2.0mL
NO GEL ACCEPTED
Other acceptable samples: EDTA plasma 2.0mL
Minimum Volume
1.0mL
Other Acceptable Specimens
2 mL Plasma from a lavender-top (EDTA-no gel)
Transport Container
2 PLAIN RED
Transport Temperature
REF - 6 DAYS
Methodology
NMR (NUCLEAR MAGNETIC RESONANCE)
Setup Schedule
Set Up:
Report Available:
Report Available:
Reference Range
LIPOPROTEI-NMR |
Clinical Significance
The key role of apolipoprotein B (apoB) particles in the pathogenesis of cardiovascular disease is well recognized. A majority (90%-95%) of these apoB particles are low-density lipoprotein particles. While low-density lipoprotein cholesterol (LDL-C) remains the primary focus for cardiovascular risk assessment and evaluation of pharmacologic effectiveness based on treatment target goals, evidence indicates that a narrow focus on LDL-C assessment and treatment alone is not the optimal strategy for patient care.
Several studies have shown that quantitative measures of LDL particle concentrations, assessed by either nuclear magnetic resonance (NMR) or apolipoprotein B, are associated with cardiovascular disease to a much greater extent than either LDL size or LDL-C. This is due to the 1:1 relationship of apoB to non-HDL particles, meaning there is 1 apoB per LDL, IDL, Lp(a), VLDL, and chylomicron particles.
Several studies have shown that quantitative measures of LDL particle concentrations, assessed by either nuclear magnetic resonance (NMR) or apolipoprotein B, are associated with cardiovascular disease to a much greater extent than either LDL size or LDL-C. This is due to the 1:1 relationship of apoB to non-HDL particles, meaning there is 1 apoB per LDL, IDL, Lp(a), VLDL, and chylomicron particles.
Performing Laboratory
LABCORP- REFERENCE LABORATORY